Allergan Inc. v. Alcon Inc.
1:04-cv-00968
📡 5G SEP • ETSI DeclaredOverview
Parties
Defendant
Alcon Laboratories, Incorporated NPE (Individual / Inventor)
Represented By
4 Attorneys ListedShaw Keller LLP
300 Delaware Avenue, Suite 1120, Wilmington, DE 19801
Young, Conaway, Stargatt & Taylor LLP
Rodney Square, 1000 North King Street
Young, Conaway, Stargatt & Taylor LLP
Rodney Square, 1000 North King Street
Baird Mandalas LLC
Baird Mandalas LLC, 103 South Bradford Street
Alcon Inc. Operating Company
Represented By
4 Attorneys ListedShaw Keller LLP
300 Delaware Avenue, Suite 1120, Wilmington, DE 19801
Young, Conaway, Stargatt & Taylor LLP
Rodney Square, 1000 North King Street
Young, Conaway, Stargatt & Taylor LLP
Rodney Square, 1000 North King Street
Baird Mandalas LLC
Baird Mandalas LLC, 103 South Bradford Street
Plaintiff
Allergan Sales LLC Operating Company
Represented By
2 Attorneys ListedFish & Richardson, P.C.
222 Delaware Avenue, 17th Floor, P.O. Box 1114
Fish & Richardson, P.C.
919 N. Market Street, Suite 1100, P.O. Box 1114
Alcon Research Ltd. Operating Company
Represented By
3 Attorneys ListedShaw Keller LLP
300 Delaware Avenue, Suite 1120, Wilmington, DE 19801
Young, Conaway, Stargatt & Taylor LLP
Rodney Square, 1000 North King Street
Baird Mandalas LLC
Baird Mandalas LLC, 103 South Bradford Street
Allergan Inc. Operating Company
Represented By
2 Attorneys ListedFish & Richardson, P.C.
222 Delaware Avenue, 17th Floor, P.O. Box 1114
Fish & Richardson, P.C.
919 N. Market Street, Suite 1100, P.O. Box 1114
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360° Radar 12 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| 🇺🇸 United States | US 6,641,834 B2 Asserted | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 2004006368 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 2004021921 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 2004021482 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 2005002692 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 8,858,961 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 9,295,641 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 9,687,443 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 10,307,368 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 2020006957 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 21,820,000 P | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 6,627,210 B2 | US Continuation / Sibling | View Official Patent → |
No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.
Standard Essential Patent (SEP) & FRAND Intelligence
5G SEP • ETSI Declared High-Probability SEP ActionEssential standard specifications, SSO declaration status, and FRAND antitrust defense evaluation
Injunction Restrictions & FRAND Defense Leverage (CJEU Huawei v. ZTE Framework)
Permanent Injunction RestrictedAsserted by recognized SEP declarant. Under the CJEU Huawei v. ZTE test, injunctions are barred if the defendant qualifies as a willing licensee.
Patents Involved
There are 2 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US6641834
Compositions containing alpha-2-adrenergic agonist components
|
Filed: 2002-09-06
Issued: 2003-11-04
|
Expired (Term Ended)
Expires: 2021-07-28
|
|
|
US6673337
Compositions containing alpha-2-adrenergic agonist components
|
Filed: 2002-11-19
Issued: 2004-01-06
|
Expired (Term Ended)
Expires: 2021-07-26
|
Patent Enforceability & Injunction Risk Assessment
Statutorily Barred — Patent expired. Under 35 U.S.C. § 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.
Standard Statutory Term — No obviousness-type double patenting truncation noted.
Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).
Procedural Motions & Interlocutory Orders
Total Motions
96
Dispositive
18
Granted
5
Denied
2
Pending / Review
43
Motions by Category
Key Dispositive Motions & Rulings